NASDAQ:NTEC

Intec Pharma (NTEC) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: N/A
50-Day Range: $9.15
▼
$36.20
52-Week Range: N/A

Volume: 988,300 shs
Average Volume: 543,436 shs
Market Capitalization: $8.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Financials Insider Trades Institutional Ownership Headlines Options Chain SEC Filings Short Interest Social Media

About Intec Pharma (NASDAQ:NTEC) Stock

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

Receive NTEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intec Pharma and its competitors with MarketBeat's FREE daily newsletter.

NTEC Stock News Headlines

May 12, 2023 | marketwatch.com

10-Q: INDAPTUS THERAPEUTICS, INC.

May 10, 2023 | marketwatch.com

Fibromyalgia Treatment Market Research | 2023-2030

June 3, 2023 | Vector Vest (Ad)

Master the Market: Free Stock Analysis + Buy/Sell/Hold Signals!

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

May 9, 2023 | marketwatch.com

Early Pregnancy Test Kit Market May Set Epic Growth Story Major Players – Abbott, Church & Dwight, SPD Swiss Precision Diagnostics GmbH

May 4, 2023 | marketwatch.com

Fibromyalgia Treatment Market Share, Size, Financial Summaries Analysis from 2023 to 2028

April 28, 2023 | marketwatch.com

Fibromyalgia Treatment Market Share by 2031

April 24, 2023 | ca.finance.yahoo.com

Intec Pharma Ltd (5NU.SG)

March 30, 2023 | marketwatch.com

Fibromyalgia Treatment Market Size, Share, Outlook and Forecast to 2031

June 3, 2023 | Behind the Markets (Ad)

NOTICE: Your retirement is in immediate danger

Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>

March 18, 2023 | markets.businessinsider.com

Maxim Group Reaffirms Their Buy Rating on Indaptus Therapeutics (INDP)

March 2, 2023 | marketwatch.com

Fibromyalgia Treatment Market Forecast: An Analysis of Industry Trends for 2023-2028

February 19, 2023 | marketwatch.com

Global Parkinson’s Disease Treatment Market Opportunities, Business Statistics Research Report 2030 By VMReports

February 15, 2023 | marketwatch.com

Fibromyalgia Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of Solutions

January 30, 2023 | marketwatch.com

Syphilis Rapid Test Kit Market : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2028

January 23, 2023 | marketwatch.com

Fibromyalgia Treatment Market Industry Updates, New Opportunities, Major Strategies, And Forecast 2028

December 29, 2022 | marketwatch.com

With 1.7% CAGR, Fibromyalgia Treatment Market 2023 Is Flourishing Around the World by 2028 | 116 Pages Report

December 21, 2022 | marketwatch.com

Fibromyalgia Treatment Market (New Report) to Witness A Pronounce Growth During 2023-2028 | 116 Pages Report

October 17, 2022 | marketwatch.com

Fibromyalgia Treatment Market Size in 2022 with Latest Report of 100 Pages & Business Forecast up to 2028 by Value Chain Analysis | No of Pages 100

August 28, 2022 | marketwatch.com

Fibromyalgia Treatment Market Size and Share 2022 Analysis Report by Industry Trends, Drivers, Applications, Sale and Forecast to 2028

July 5, 2022 | investing.com

World Holdings Co Ltd (2429)

June 4, 2022 | finanznachrichten.de

Beroe Inc.: Beroe partners with Mintec to power its intelligence offering with market-leading commodity price data

December 18, 2021 | finanznachrichten.de

EXEL INDUSTRIES :2020-2021 Full-year results: Significant improvement in margins combined with a sharp reduction in debt

December 10, 2021 | yahoo.com

Dataiku Increases Commitment to the Japanese Market to Accelerate Everyday AI in Japan

December 1, 2021 | markets.businessinsider.com

Genetron earnings preview: what Wall Street is expecting

November 12, 2021 | markets.businessinsider.com

Here's what Wall Street expects from Cipher Pharmaceuticals's earnings

August 3, 2021 | finance.yahoo.com

Intec Closes Merger with Decoy Biosystems

August 3, 2021 | finance.yahoo.com

Intec Announces Expected Closing Date of Decoy Merger

See More Headlines

NTEC Company Calendar

Last Earnings: 5/17/2021
Today: 6/03/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NTEC
CUSIP: N/A
CIK: 1638381
Web: www.intecpharma.com
Phone: (722) 586-4657
Fax: N/A
Employees: 40
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($16.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,130,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -96.37%
Return on Assets: -68.87%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.34
Quick Ratio: 2.34

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $16.18 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 898,000
Free Float: N/A
Market Cap: $8.65 million
Optionable: Optionable
Beta: 0.83

Key Executives

Jeffrey A. Meckler
Vice Chairman & Chief Executive Officer

Nir Sassi
President & Chief Financial Officer

Michael James Newman
Director & Chief Scientific Officer

Anna Hotovely-Salomon
Director-Clinical Affairs

Walt A. Linscott
Chief Business Officer

Key Competitors

View All Competitors

NTEC Stock - Frequently Asked Questions

How were Intec Pharma's earnings last quarter?: Intec Pharma Ltd (NASDAQ:NTEC) issued its quarterly earnings data on Monday, May, 17th. The biotechnology company reported ($3.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.48) by $0.36.
When did Intec Pharma's stock split?: Intec Pharma's stock reverse split on the morning of Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.
What other stocks do shareholders of Intec Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Nabriva Therapeutics (NBRV), Onconova Therapeutics (ONTX), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), T2 Biosystems (TTOO) and Acasti Pharma (ACST).

When did Intec Pharma IPO?: (NTEC) raised $30 million in an initial public offering on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.
What is Intec Pharma's stock symbol?: Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."
How much money does Intec Pharma make?: Intec Pharma (NASDAQ:NTEC) has a market capitalization of $0.00. The biotechnology company earns $-14,130,000.00 in net income (profit) each year or ($16.32) on an earnings per share basis.
How can I contact Intec Pharma?: Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The official website for the company is www.intecpharma.com. The biotechnology company can be reached via phone at (722) 586-4657 or via email at ir@intec-us.com.

This page (NASDAQ:NTEC) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Intec Pharma (NTEC) Stock Forecast, Price & News

About Intec Pharma (NASDAQ:NTEC) Stock

NTEC Stock News Headlines

NTEC Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NTEC Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info